News

All Sci
allsci. com > news > licensing-deals > helix-secures-astrazeneca-partnership-to-power-drug-discovery-with-us-genomic-data

Astra Zeneca Partners with Helix for Drug Discovery

5+ hour, 40+ min ago  (344+ words) All Sci Astra Zeneca has signed a multi-year agreement with San Mateo-based Helix to access its Geno Sphere clinico-genomic cohort platform for drug discovery and development, adding a major US commercial data source to its existing population genomics infrastructure. The…...

Symbols: nyse:tmo
Google News
allsci. com > press-release > xiaflex-wins-first-ever-fda-approval-pathway-for-plantar-fibromatosis-with-phase-iii-success

Xiaflex Wins FDA Approval for Plantar Fibromatosis

2+ hour, 31+ min ago  (475+ words) Xiaflex wins first-ever FDA approval pathway for plantar fibromatosis with Phase III success All Sci Keenova Therapeutics has reported that collagenase clostridium histolyticum (Xiaflex) met its primary endpoint in a pivotal Phase III trial for plantar fibromatosis " a condition also…...

Symbols: nasdaq:fblg
Google News
allsci. com > news > licensing-deals > boehringer-ingelheim-acquires-viral-vector-platform-from-prime-vector-technologies-for-cancer-vaccines

Boehringer Ingelheim Acquires Cancer Vaccine Platform

5+ hour, 35+ min ago  (485+ words) Boehringer Ingelheim acquires viral vector platform for cancer vaccines from Prime Vector All Sci Boehringer Ingelheim has entered a license agreement with Germany-based Prime Vector Technologies Gmb H (PVT) to acquire exclusive rights to its Orf virus (ORFV) viral vector…...

Symbols: nasdaq:anix
All Sci
allsci. com > news > funding > grants > chicago-uni-engineers-bacteria-to-deliver-immunotherapy-directly-to-pancreatic-tumors

UChicago Engineers Bacteria for Pancreatic Cancer

5+ hour, 39+ min ago  (331+ words) All Sci The University of Chicago has received a USD 1. 75 million National Cancer Institute R01 award to develop genetically engineered Bifidobacterium as a systemic delivery vehicle for immunotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC), one of the cancers least responsive to…...

Symbols: asx:osl
All Sci
allsci. com > news > approvals > beckman-coulters-ce-marked-p-tau217-blood-test-enables-scalable-alzheimers-screening-in-routine-labs

Beckman Coulter's CE-Marked p-Tau217 Blood Test

1+ day, 6+ hour ago  (557+ words) enables scalable Alzheimer's screening in routine labs All Sci Beckman Coulter has become the latest diagnostics company to secure European regulatory clearance for a blood-based Alzheimer's biomarker assay, underscoring intensifying competition to supply scalable patient-selection tools as disease-modifying therapies expand....

Symbols: six:ro
All Sci
allsci. com > news > funding > grants > vcu-advances-dual-egfr-her2-degradation-strategy-to-overcome-drug-resistance-in-lung-cancer

VCU Advances Dual EGFR/HER2 Lung Cancer Strategy

1+ day, 6+ hour ago  (300+ words) All Sci Virginia Commonwealth University (VCU) has received a USD 1. 74 million National Cancer Institute R01 award to advance preclinical evaluation of PEPDG278 D, a recombinant human protein designed to degrade both EGFR and HER2 in non-small cell lung cancer " including tumors resistant to…...

Symbols: asx:rac
All Sci
allsci. com > news > clinical-trials > agenus-posts-three-year-survival-data-for-botensilimab-in-mss-colorectal-cancer

Agenus Achieves 33% Three-Year Survival in Colorectal Cancer

2+ day, 1+ hour ago  (716+ words) All Sci Agenus Inc. (Nasdaq: AGEN) reported three-year overall survival data from its Phase Ib C-800-01 trial at ESMO GI 2026 in Munich, showing that 33% of patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer without active liver metastases were alive at 36 months…...

Symbols: nasdaq:agen
All Sci
allsci. com > news > clinical-trials > multitude-presents-early-clinical-validation-for-cdh17-adc-in-colorectal-cancer

CDH17 Antibody-Drug Conjugate Shows Promise in. ..

2+ day, 4+ hour ago  (720+ words) All Sci Interim Phase I data from China-based Multitude Therapeutics reported a 20% overall response rate and a 91% disease control rate for AMT-676, a CDH17-directed antibody-drug conjugate, in heavily pretreated metastatic colorectal cancer patients " results that, while early, suggest the target…...

Symbols: btc-usd
All Sci
allsci. com > news > clinical-trials > brii-bios-hbv-combo-strategy-validated-but-vir-dispute-clouds-phase-iii-path

Brii Bio's Hepatitis B Strategy Validated

2+ day, 5+ hour ago  (653+ words) All Sci Brii Biosciences Limited, dual-head-quartered in Beijing, China, and North Carolina, reported end-of-treatment data from two Phase IIb studies that clarify the optimal combination strategy for BRII-179 in chronic HBV. However, a legal dispute with Vir Biotechnology (Nasdaq: VIR)…...

Symbols: nasdaq:abus,nasdaq:gild
Google News
allsci. com > news > funding > grants > memorial-sloan-kettering-builds-diverse-stem-cell-knockout-catalog-to-study-autism-and-type-2-diabetes-genes

MSK Builds Diverse Stem Cell Knockout Catalog

6+ day, 55+ min ago  (288+ words) All Sci Memorial Sloan-Kettering Cancer Center has received a USD 1. 78 million NIH UM1 renewal to continue building a large-scale catalog of human gene knockout phenotypes across genetically diverse stem cell lines " work that could sharpen understanding of how gene loss drives…...

Symbols: btc-usd,cls.to,cco.to,pain.v,ineo.v,elem.cn